Vertex Pharmaceuticals annual working capital
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Vertex Pharmaceuticals Working Capital Growth & History (VRTX)
Vertex Pharmaceuticals's working capital was $7.34B for fiscal 2025.
View full Vertex Pharmaceuticals company overviewVertex Pharmaceuticals annual working capital history
| Fiscal year | Period ended | Working capital | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $7.34B | $1.31B | +21.69% |
| 2024 | 2024-12-31 | $6.03B | −$4.57B | −43.08% |
| 2023 | 2023-12-31 | $10.60B | $104.1M | +0.99% |
| 2022 | 2022-12-31 | $10.49B | $3.07B | +41.44% |
| 2021 | 2021-12-31 | $7.42B | $1.16B | +18.59% |
| 2020 | 2020-12-31 | $6.26B | $2.77B | +79.35% |
| 2019 | 2019-12-31 | $3.49B | $765.2M | +28.10% |
| 2018 | 2018-12-31 | $2.72B | $881.1M | +47.84% |
| 2017 | 2017-12-31 | $1.84B | $802.7M | +77.26% |
| 2016 | 2016-12-31 | $1.04B | $138.0M | +15.32% |
| 2015 | 2015-12-31 | $901.0M | −$277.3M | −23.53% |
| 2014 | 2014-12-31 | $1.18B | −$12.5M | −1.05% |
| 2013 | 2013-12-31 | $1.19B | $33.8M | +2.92% |
| 2012 | 2012-12-31 | $1.16B | $218.1M | +23.22% |
| 2011 | 2011-12-31 | $938.9M | $356.6M | +61.25% |
| 2010 | 2010-12-31 | $582.3M | −$439.9M | −43.04% |
| 2009 | 2009-12-31 | $1.02B | — | — |
Vertex Pharmaceuticals quarterly working capital
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Working capital | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $8.61B | $2.32B | +36.83% |
| Q1 2026 | 2026-03-31 | $7.85B | $1.62B | +26.09% |
| Q4 2025 | 2025-12-31 | $7.34B | $1.31B | +21.69% |
| Q3 2025 | 2025-09-30 | $6.09B | $263.3M | +4.52% |
| Q2 2025 | 2025-06-30 | $6.29B | $895.1M | +16.59% |
| Q1 2025 | 2025-03-31 | $6.23B | −$3.27B | −34.42% |
| Q4 2024 | 2024-12-31 | $6.03B | −$4.57B | −43.08% |
| Q3 2024 | 2024-09-30 | $5.83B | −$5.27B | −47.45% |
| Q2 2024 | 2024-06-30 | $5.39B | −$5.13B | −48.73% |
| Q1 2024 | 2024-03-31 | $9.49B | −$446.7M | −4.49% |
| Q4 2023 | 2023-12-31 | $10.60B | $104.1M | +0.99% |
| Q3 2023 | 2023-09-30 | $11.10B | $1.43B | +14.85% |
| Q2 2023 | 2023-06-30 | $10.52B | $1.57B | +17.59% |
| Q1 2023 | 2023-03-31 | $9.94B | $1.76B | +21.49% |
| Q4 2022 | 2022-12-31 | $10.49B | $3.07B | +41.44% |
| Q3 2022 | 2022-09-30 | $9.66B | $2.72B | +39.25% |
| Q2 2022 | 2022-06-30 | $8.95B | $2.33B | +35.13% |
| Q1 2022 | 2022-03-31 | $8.18B | $1.59B | +24.05% |
| Q4 2021 | 2021-12-31 | $7.42B | $1.16B | +18.59% |
| Q3 2021 | 2021-09-30 | $6.94B | $1.48B | +27.20% |
| Q2 2021 | 2021-06-30 | $6.62B | $1.73B | +35.24% |
| Q1 2021 | 2021-03-31 | $6.60B | $2.69B | +68.78% |
| Q4 2020 | 2020-12-31 | $6.26B | $2.77B | +79.35% |
| Q3 2020 | 2020-09-30 | $5.45B | $2.07B | +60.98% |
| Q2 2020 | 2020-06-30 | $4.90B | $1.44B | +41.83% |
| Q1 2020 | 2020-03-31 | $3.91B | $831.1M | +27.01% |
| Q4 2019 | 2019-12-31 | $3.49B | $765.2M | +28.10% |
| Q3 2019 | 2019-09-30 | $3.39B | $694.1M | +25.76% |
| Q2 2019 | 2019-06-30 | $3.45B | $971.6M | +39.18% |
| Q1 2019 | 2019-03-31 | $3.08B | $862.8M | +38.97% |
| Q4 2018 | 2018-12-31 | $2.72B | $881.1M | +47.84% |
| Q3 2018 | 2018-09-30 | $2.69B | $1.08B | +66.59% |
| Q2 2018 | 2018-06-30 | $2.48B | $925.0M | +59.48% |
| Q1 2018 | 2018-03-31 | $2.21B | $831.8M | +60.19% |
| Q4 2017 | 2017-12-31 | $1.84B | $802.7M | +77.26% |
| Q3 2017 | 2017-09-30 | $1.62B | $838.2M | +107.59% |
| Q2 2017 | 2017-06-30 | $1.56B | $723.9M | +87.08% |
| Q1 2017 | 2017-03-31 | $1.38B | $531.2M | +62.44% |
| Q4 2016 | 2016-12-31 | $1.04B | $138.0M | +15.32% |
| Q3 2016 | 2016-09-30 | $779.1M | −$205.4M | −20.87% |
| Q2 2016 | 2016-06-30 | $831.3M | −$89.6M | −9.73% |
| Q1 2016 | 2016-03-31 | $850.8M | −$205.0M | −19.41% |
| Q4 2015 | 2015-12-31 | $901.0M | −$277.3M | −23.53% |
| Q3 2015 | 2015-09-30 | $984.5M | −$293.4M | −22.96% |
| Q2 2015 | 2015-06-30 | $920.9M | −$63.5M | −6.46% |
| Q1 2015 | 2015-03-31 | $1.06B | −$1.1M | −0.10% |
| Q4 2014 | 2014-12-31 | $1.18B | −$12.5M | −1.05% |
| Q3 2014 | 2014-09-30 | $1.28B | $38.8M | +3.13% |
| Q2 2014 | 2014-06-30 | $984.4M | −$350.5M | −26.26% |
| Q1 2014 | 2014-03-31 | $1.06B | −$101.3M | −8.75% |
| Q4 2013 | 2013-12-31 | $1.19B | $33.8M | +2.92% |
| Q3 2013 | 2013-09-30 | $1.24B | $11.3M | +0.92% |
| Q2 2013 | 2013-06-30 | $1.33B | $121.3M | +10.00% |
| Q1 2013 | 2013-03-31 | $1.16B | $78.8M | +7.31% |
| Q4 2012 | 2012-12-31 | $1.16B | $218.1M | +23.22% |
| Q3 2012 | 2012-09-30 | $1.23B | $530.9M | +76.19% |
| Q2 2012 | 2012-06-30 | $1.21B | $865.4M | +248.58% |
| Q1 2012 | 2012-03-31 | $1.08B | $622.5M | +136.28% |
| Q4 2011 | 2011-12-31 | $938.9M | $356.6M | +61.25% |
| Q3 2011 | 2011-09-30 | $696.9M | −$218.0M | −23.83% |
| Q2 2011 | 2011-06-30 | $348.2M | −$364.0M | −51.11% |
| Q1 2011 | 2011-03-31 | $456.8M | −$458.4M | −50.09% |
| Q4 2010 | 2010-12-31 | $582.3M | −$439.9M | −43.04% |
| Q3 2010 | 2010-09-30 | $914.9M | — | — |
| Q2 2010 | 2010-06-30 | $712.2M | — | — |
| Q1 2010 | 2010-03-31 | $915.2M | — | — |
| Q4 2009 | 2009-12-31 | $1.02B | — | — |
Vertex Pharmaceuticals working capital trends
Over the last five fiscal years, Vertex Pharmaceuticals's working capital increased from $6.26B to $7.34B, a change of $1.08B. The latest reported quarter, Q2 2026, shows $8.61B.
About the metric
What working capital means
Working capital is the difference between current assets and current liabilities. It provides a snapshot of short-term operating liquidity, although negative working capital can be normal for some business models and the measure is often not meaningful for banks.
Calculation and source
How working capital is calculated
TickerStat calculates working capital as reported current assets minus reported current liabilities at the same balance-sheet date. Missing current classifications are not assumed to be zero. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Vertex Pharmaceuticals source filings ↗